$GMED
GLOBUS MEDICAL INC Stock $gmed

$gmed Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000123783118000033 Filed on August 02, 2018

Income Statement

Concept	2018 Q2	2017 Q2
Revenue	$173.4M	$152.4M
YoY Change	13.78%	10.84%
Cost Of Revenue	$37.64M	$37.20M
YoY Change	1.18%	13.65%
Gross Profit	$135.7M	$115.2M
YoY Change	17.85%	9.96%
Gross Profit Margin	78.29%	75.59%
Selling, General & Admin	$77.13M	$64.44M
YoY Change	19.69%	20.87%
% of Gross Profit	56.82%	55.94%
Research & Development	$13.52M	$10.71M
YoY Change	26.23%	1.12%
% of Gross Profit	9.96%	9.3%
Depreciation & Amortization	$9.700M	$10.70M
YoY Change	-9.35%	52.86%
% of Gross Profit	7.15%	9.29%
Operating Expenses	$93.61M	$77.82M
YoY Change	20.29%	16.43%
Operating Profit	$42.14M	$37.37M
YoY Change	12.76%	-1.44%
Interest Expense	$3.300M	$2.000M
YoY Change	65.0%	566.67%
% of Operating Profit	7.83%	5.35%
Other Income/Expense, Net	$8.165M	$2.186M
YoY Change	273.51%	422.97%
Pretax Income	$50.30M	$39.56M
YoY Change	27.17%	3.18%
Income Tax	$5.327M	$10.89M
% Of Pretax Income	10.59%	27.53%
Net Earnings	$44.98M	$28.67M
YoY Change	56.89%	11.09%
Net Earnings / Revenue	25.94%	18.81%
Basic Earnings Per Share	$0.46	$0.30
Diluted Earnings Per Share	$0.44	$0.29
COMMON SHARES
Basic Shares Outstanding	97.83M shares	96.16M shares
Diluted Shares Outstanding	101.5M shares	97.82M shares

Balance Sheet

Concept	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$360.9M	$312.2M
YoY Change	15.61%	-3.79%
Cash & Equivalents	$119.9M	$88.74M
Short-Term Investments	$241.0M	$162.5M
Other Short-Term Assets	$16.90M	$6.400M
YoY Change	164.06%	-61.45%
Inventory	$114.8M	$111.1M
Prepaid Expenses
Receivables	$118.6M	$95.49M
Other Receivables	$22.00M	$10.00M
Total Short-Term Assets	$633.2M	$535.1M
YoY Change	18.33%	-0.06%
LONG-TERM ASSETS
Property, Plant & Equipment	$154.3M	$130.1M
YoY Change	18.61%	9.28%
Goodwill	$123.8M	$112.8M
YoY Change	9.74%	22.62%
Intangibles	$74.97M	$90.04M
YoY Change	-16.73%	172.89%
Long-Term Investments	$155.9M	$60.90M
YoY Change	155.99%	-7.16%
Other Assets	$7.202M	$1.051M
YoY Change	585.25%	248.01%
Total Long-Term Assets	$560.6M	$459.9M
YoY Change	21.9%	37.67%
TOTAL ASSETS
Total Short-Term Assets	$633.2M	$535.1M
Total Long-Term Assets	$560.6M	$459.9M
Total Assets	$1.194B	$995.0M
YoY Change	19.98%	14.44%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$20.73M	$16.29M
YoY Change	27.23%	40.1%
Accrued Expenses	$47.98M	$41.71M
YoY Change	15.04%	-12.91%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$80.28M	$69.06M
YoY Change	16.25%	-1.73%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.561M	$1.802M
YoY Change	42.12%	5.07%
Total Long-Term Liabilities	$2.561M	$1.802M
YoY Change	42.12%	5.07%
TOTAL LIABILITIES
Total Short-Term Liabilities	$80.28M	$69.06M
Total Long-Term Liabilities	$2.561M	$1.802M
Total Liabilities	$96.65M	$89.71M
YoY Change	7.73%	-0.26%
SHAREHOLDERS EQUITY
Retained Earnings	$820.8M	$686.3M
YoY Change	19.6%	18.66%
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.097B	$905.3M
YoY Change
Total Liabilities & Shareholders Equity	$1.194B	$995.0M
YoY Change	19.98%	14.44%

Cashflow Statement

Concept	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	$44.98M	$28.67M
YoY Change	56.89%	11.09%
Depreciation, Depletion And Amortization	$9.700M	$10.70M
YoY Change	-9.35%	52.86%
Cash From Operating Activities	$33.30M	$26.00M
YoY Change	28.08%	9.24%
INVESTING ACTIVITIES
Capital Expenditures	-$14.80M	-$13.60M
YoY Change	8.82%	27.1%
Acquisitions
YoY Change
Other Investing Activities	-$40.70M	-$34.30M
YoY Change	18.66%
Cash From Investing Activities	-$55.40M	-$47.90M
YoY Change	15.66%	343.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	23.30M	3.700M
YoY Change	529.73%	236.36%
NET CHANGE
Cash From Operating Activities	33.30M	26.00M
Cash From Investing Activities	-55.40M	-47.90M
Cash From Financing Activities	23.30M	3.700M
Net Change In Cash	1.200M	-18.20M
YoY Change	-106.59%	-229.08%
FREE CASH FLOW
Cash From Operating Activities	$33.30M	$26.00M
Capital Expenditures	-$14.80M	-$13.60M
Free Cash Flow	$48.10M	$39.60M
YoY Change	21.46%	14.78%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001237831
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	98254456	shares
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	GLOBUS MEDICAL INC
CY2017Q4	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	1177000	USD
CY2018Q2	gmed	Accrued Liabilities Legal And Other Settlements And Expenses AccruedLiabilitiesLegalAndOtherSettlementsAndExpenses	1369000	USD
CY2017Q2	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-233000	USD
	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-5234000	USD
CY2018Q2	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-510000	USD
	gmed	Business Acquisition Contingent Consideration Milestone Payment BusinessAcquisitionContingentConsiderationMilestonePayment	-5950000	USD
CY2017Q4	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	11411000	USD
CY2018Q2	gmed	Business Acquisition Liabilities Current BusinessAcquisitionLiabilitiesCurrent	6507000	USD
CY2017Q4	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	4508000	USD
CY2018Q2	gmed	Business Acquisition Liabilities Noncurrent BusinessAcquisitionLiabilitiesNoncurrent	3815000	USD
CY2017Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	4871000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	4871000	USD
CY2018Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	0	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Additions For Current Period Acquisitions BusinessCombinationContingentConsiderationArrangementsFairValueAdditionsForCurrentPeriodAcquisitions	0	USD
CY2017Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	333000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	811000	USD
CY2018Q2	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	182000	USD
	gmed	Business Combination Contingent Consideration Arrangements Fair Value Change In Fair Value Liability BusinessCombinationContingentConsiderationArrangementsFairValueChangeInFairValueLiability	416000	USD
CY2017Q2	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	42000	USD
	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	42000	USD
CY2018Q2	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	-204000	USD
	gmed	Contingentconsiderationcurrencytranslationlossgain Contingentconsiderationcurrencytranslationlossgain	-63000	USD
CY2017Q4	gmed	Intangible Assets Gross IntangibleAssetsGross	93197000	USD
CY2018Q2	gmed	Intangible Assets Gross IntangibleAssetsGross	94000000	USD
	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	5234000	USD
	gmed	Payment Of Business Acquisition Liabilities PaymentOfBusinessAcquisitionLiabilities	5950000	USD
CY2018Q2	gmed	Prepaidroyalty Prepaidroyalty	9000000	USD
CY2018Q2	gmed	Share Based Compensation Number Of Stock Plans ShareBasedCompensationNumberOfStockPlans	3
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	25039000	USD
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	20727000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	116676000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	118561000	USD
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	3274000	USD
CY2018Q2	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	2979000	USD
CY2018Q2	us-gaap	Accrued Liabilities And Other Liabilities AccruedLiabilitiesAndOtherLiabilities	2500000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	52594000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	47978000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2139000	USD
CY2018Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2435000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	191760000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	204760000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-8642000	USD
CY2017Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-5872000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6907000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-6807000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	238341000	USD
CY2018Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	283132000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11661000	USD
CY2017Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3571000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	7062000	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5480000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11533000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3963000	USD
CY2018Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3924000	USD
CY2017Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1809000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3591000	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2178000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	4365000	USD
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2017000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3887000	shares
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1809000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1863000	shares
CY2017Q4	us-gaap	Assets Assets	1078502000	USD
CY2018Q2	us-gaap	Assets Assets	1193833000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	620342000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	633224000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	254890000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	240976000	USD
CY2017Q4	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	56133000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities Noncurrent AvailableForSaleSecuritiesDebtSecuritiesNoncurrent	155859000	USD
CY2017Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	617000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1005000	USD
CY2018Q2	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	782000	USD
	us-gaap	Business Combination Acquisition Related Costs BusinessCombinationAcquisitionRelatedCosts	1021000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	811000	USD
	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	416000	USD
CY2016Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	19849000	USD
CY2017Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	15326000	USD
CY2017Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	20339000	USD
CY2017Q4	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	15919000	USD
CY2018Q1	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10854000	USD
CY2018Q2	us-gaap	Business Combination Contingent Consideration Liability BusinessCombinationContingentConsiderationLiability	10322000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	5700000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	6800000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	66954000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	88744000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	118817000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	119944000	USD
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67431000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	89222000	USD
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	118817000	USD
CY2018Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	119944000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	21791000	USD
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1127000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	785000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	96657881	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	98247744	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	96657881	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	98247744	shares
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	28876000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	60151000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	40936000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	84616000	USD
CY2017Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37199000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	72799000	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	37637000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	75607000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-4238000	USD
	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	1429000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	755000	USD
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2089000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	20031000	USD
CY2018Q2	us-gaap	Deferred Tax Assets Liabilities Net Noncurrent DeferredTaxAssetsLiabilitiesNetNoncurrent	17816000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	10669000	USD
CY2018Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	9991000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22935000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	19233000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.60
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.87
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.29
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.59
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.44
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.84
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	450000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-71000	USD
CY2017Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.275
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.300
CY2018Q2	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.106
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.141
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	29006000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	25950000	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	47000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	98000	USD
CY2018Q2	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	71000	USD
	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	128000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	14538000	USD
CY2018Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	19027000	USD
CY2017Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	448000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	996000	USD
CY2018Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	344000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	339000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	3947000	USD
CY2016Q4	us-gaap	Goodwill Goodwill	105926000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	123890000	USD
CY2018Q2	us-gaap	Goodwill Goodwill	123750000	USD
CY2017	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	57000	USD
	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-140000	USD
CY2017	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	17907000	USD
	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	0	USD
CY2017Q2	us-gaap	Gross Profit GrossProfit	115191000	USD
	us-gaap	Gross Profit GrossProfit	235400000	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	135747000	USD
	us-gaap	Gross Profit GrossProfit	272188000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	39557000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	81971000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	50304000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	98382000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	10890000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	24590000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	5327000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13866000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	35475000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	22667000	USD
CY2017Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	8717000	USD
CY2018Q2	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	18709000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1660000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-5751000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3172000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2257000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3303000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-6825000	USD
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-10276000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-4497000	USD
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2104000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4652000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11120000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-8506000	USD
CY2017Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1657000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	1404000	shares
CY2018Q2	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3680000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3668000	shares
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	78659000	USD
CY2018Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	74973000	USD
CY2017Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	1590000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	3008000	USD
CY2018Q2	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	2971000	USD
	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	5262000	USD
	us-gaap	Interest Paid InterestPaid	21000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	78413000	USD
CY2018Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	86646000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	108409000	USD
CY2018Q2	us-gaap	Inventory Net InventoryNet	114758000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	19984000	USD
CY2018Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	18909000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	10012000	USD
CY2018Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	9203000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	4962000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	5406000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1855000	USD
	us-gaap	Investment Income Amortization Of Premium InvestmentIncomeAmortizationOfPremium	1477000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	110724000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	96647000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1078502000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1193833000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93073000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	80280000	USD
	us-gaap	Loans Receivable Description Of Variable Rate Basis LoansReceivableDescriptionOfVariableRateBasis	LIBOR
CY2017Q2	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	243000	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	243000	USD
CY2018Q2	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
	us-gaap	Loss Contingency Accrual Provision LossContingencyAccrualProvision	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	677000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	27181000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-58762000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-111547000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	79426000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	85564000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	28667000	USD
	us-gaap	Net Income Loss NetIncomeLoss	57381000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	44977000	USD
	us-gaap	Net Income Loss NetIncomeLoss	84516000	USD
CY2017Q4	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	1667000	USD
CY2018Q2	us-gaap	Notes And Loans Receivable Gross Current NotesAndLoansReceivableGrossCurrent	3333000	USD
CY2017Q4	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	28333000	USD
CY2018Q2	us-gaap	Notes And Loans Receivable Gross Noncurrent NotesAndLoansReceivableGrossNoncurrent	26667000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	77820000	USD
	us-gaap	Operating Expenses OperatingExpenses	157715000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	93608000	USD
	us-gaap	Operating Expenses OperatingExpenses	184415000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	37371000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	77685000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	42139000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	87773000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	13947000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	12538000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7947000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7202000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	186000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2627000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-4205000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	172000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	2772000	USD
	us-gaap	Other Comprehensive Income Loss Before Reclassifications Net Of Tax OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax	105000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	209000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2770000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-4041000	USD
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	100000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	23000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	143000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	164000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-72000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2474000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2561000	USD
CY2017Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	148000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	282000	USD
CY2018Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	4850000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	5008000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2186000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4286000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	8165000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	10609000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	31501000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	138286000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	309223000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	25061000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	27167000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	11166000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16943000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	103398000	USD
	us-gaap	Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities	158102000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	32688000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	63741000	USD
CY2018Q2	us-gaap	Proceeds From Sale Of Other Assets1 ProceedsFromSaleOfOtherAssets1	5000000	USD
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	0	USD
	us-gaap	Proceeds From Sales Of Assets Investing Activities ProceedsFromSalesOfAssetsInvestingActivities	3000000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5911000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	33131000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	143167000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	154342000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	958000	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	312000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-2000	USD
	us-gaap	Reclassification From Accumulated Other Comprehensive Income Current Period Net Of Tax ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax	-5000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10713000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	21379000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13523000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26210000	USD
CY2016Q4	us-gaap	Restricted Cash RestrictedCash	477000	USD
CY2017Q2	us-gaap	Restricted Cash RestrictedCash	478000	USD
CY2017Q4	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2018Q2	us-gaap	Restricted Cash RestrictedCash	0	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	736247000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	820763000	USD
CY2017Q2	us-gaap	Revenues Revenues	152390000	USD
	us-gaap	Revenues Revenues	308199000	USD
CY2018Q2	us-gaap	Revenues Revenues	173384000	USD
	us-gaap	Revenues Revenues	347795000	USD
CY2017Q4	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	6325000	USD
CY2018Q2	us-gaap	Sales And Excise Tax Payable Current SalesAndExciseTaxPayableCurrent	5686000	USD
CY2017Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	64438000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	131497000	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	77125000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	152819000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7062000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	11533000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	3749000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	21.54
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2870000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	4760000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	33305000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	48153000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	229000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2454000	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.89
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.49
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	17.09
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	14.66
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	202872000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9041000	shares
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9676000	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	23.40
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	29.57
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	34.66
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	94488000	USD
CY2018Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	5927000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	20.98
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	27.23
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	46.54
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	3618000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	7160000	USD
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	5551000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1 SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1	11661000	USD
CY2018Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	108384000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y4M12D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y0M0D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y0M0D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1590000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	33131000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	967778000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	1097186000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97818000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	97483000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101510000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	101005000	shares
CY2017Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96161000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	96079000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97830000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	97337000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;">Use of Estimates </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The preparation of the condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. We base our estimates, in part, on historical experience that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of revisions are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Significant areas that require management’s estimates include intangible assets, business acquisition liabilities, allowance for doubtful accounts, stock-based compensation, write-down for excess and obsolete inventory, useful lives of assets, the outcome of litigation, recoverability of intangible assets and income taxes. We are subject to risks and uncertainties due to changes in the healthcare environment, regulatory oversight, competition, and legislation that may cause actual results to differ from estimated results. </font></div></div>

Files In Submission

Name	View Source	Status
0001237831-18-000033-index-headers.html	Edgar Link	pending
0001237831-18-000033-index.html	Edgar Link	pending
0001237831-18-000033.txt	Edgar Link	pending
0001237831-18-000033-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
gmed-20180630.xml	Edgar Link	completed
gmed-20180630.xsd	Edgar Link	pending
gmed-20180630_cal.xml	Edgar Link	unprocessable
gmed-20180630_def.xml	Edgar Link	unprocessable
gmed-20180630_lab.xml	Edgar Link	unprocessable
gmed-20180630_pre.xml	Edgar Link	unprocessable
gmed6301810q.htm	Edgar Link	pending
gmed63018ex101.htm	Edgar Link	pending
gmed63018ex311.htm	Edgar Link	pending
gmed63018ex312.htm	Edgar Link	pending
gmed63018ex32.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$GMED
GLOBUS MEDICAL INC Stock $gmed

2018 Q2 Form 10-Q Financial Statement

#000123783118000033 Filed on August 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED GLOBUS MEDICAL INC Stock $gmed

2018 Q2 Form 10-Q Financial Statement

#000123783118000033 Filed on August 02, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$GMED
GLOBUS MEDICAL INC Stock $gmed